ArticleComputational and structural biotechnology journal2021
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.
Article in Computational and structural biotechnology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Bridging the computational-experimental gap: leveraging large language model to prioritize Alzheimer's therapeutics based on comparison of learning models.npj health systems · 2026Article
- Bridging the Computational-Experimental Gap: Leveraging Large Language Model to Prioritize Alzheimer's Therapeutics Based on Comparison of Learning Models.Research square · 2025Article
- Article
- Exploring the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2024Article
- Integrative analysis of DNA methylomes reveals novel cell-free biomarkers in lung adenocarcinoma.Frontiers in genetics · 2023Article
- Article
- Article
- Plasma Metabolome Alterations Discriminate between COVID-19 and Non-COVID-19 Pneumonia.Metabolites · 2022Article
- Genetic association and single-cell transcriptome analyses reveal distinct features connecting autoimmunity with cancers.iScience · 2022Article
- Databases, Knowledgebases, and Software Tools for Virus Informatics.Advances in experimental medicine and biology · 2022Article
- Functional Roles and Targets of COVID-19 in Blood Cells Determined Using Bioinformatics Analyses.Bioinformatics and biology insights · 2022Article
- Scale bar of aging trajectories for screening personal rejuvenation treatments.Computational and structural biotechnology journal · 2022Article
- A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity.JCI insight · 2021Article
- In silico drug repurposing in COVID-19: A network-based analysis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies.Frontiers in pharmacology · 2021Review
- Transcriptomic Signatures of Airway Epithelium Infected With SARS-CoV-2: A Balance Between Anti-infection and Virus Load.Frontiers in cell and developmental biology · 2021Article
- Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery.Computational and structural biotechnology journal · 2021Review
- Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine.Frontiers in immunology · 2021Article
- Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.Computational and structural biotechnology journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The novel coronavirus SARS-CoV-2 is damaging the world's social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically evaluated the effect of SARS-CoV-2 on gene expression of both lung tissue and blood from COVID-19 patients using transcriptome profiling. Differential gene expression analysis revealed potential core mechanism of COVID-19-induced pneumonia in which IFN-α, IFN-β, IFN-γ, TNF and IL6 triggered cytokine storm mediated by neutrophil, macrophage, B and DC cells. Weighted gene correlation network analysis identified two gene modules that are highly correlated with clinical traits of COVID-19 patients, and confirmed that over-activation of immune system-mediated cytokine release syndrome is the underlying pathogenic mechanism for acute phase of COVID-19 infection. It suggested that anti-inflammatory therapies may be promising regimens for COVID-19 patients. Furthermore, drug repurposing analysis of thousands of drugs revealed that TNFα inhibitor etanercept and γ-aminobutyric acid-B receptor (GABABR) agonist baclofen showed most significant reversal power to COVID-19 gene signature, so we are highly optimistic about their clinical use for COVID-19 treatment. In addition, our results suggested that adalimumab, tocilizumab, rituximab and glucocorticoids may also have beneficial effects in restoring normal transcriptome, but not chloroquine, hydroxychloroquine or interferons. Controlled clinical trials of these candidate drugs are needed in search of effective COVID-19 treatment in current crisis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.